Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Twist Bioscience 2027 Outlook Signals Sharp Slowdown in AI Drug Discovery Growth

12 November 2026 · By · Wire by Fusion42

Published

12 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at tradingview.com →

◆ Verified

Fusion42 · 12 November 2026 · Fusion42 review

Twist Bioscience reported strong fiscal 2026 results with AI drug discovery revenue surging 175%, but its 2027 outlook signals a significant slowdown to 69% growth. Despite expanding manufacturing capacity and positive overall revenue forecasts, the deceleration in AI-driven drug discovery revenue growth indicates a cooling market.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face a slower AI drug discovery growth despite capacity growth, forcing you to sharpen cost control and customer expansion strategies now. The big jump in AI revenue last year won't repeat, so adjust your growth plans and funding expectations accordingly.

◆ Coverage

1 source · 12 Nov 2026

◆ Related on Wire

◆ Topics

Biotechai-drug-discoverybiotechrevenue-forecastmanufacturing-expansion2027-outlook